Welcome to our dedicated page for MBX Biosciences news (Ticker: MBX), a resource for investors and traders seeking the latest updates and insights on MBX Biosciences stock.
MBX Biosciences, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, and its news flow reflects progress across multiple clinical programs and corporate initiatives. Company press releases and investor updates highlight developments from its proprietary Precision Endocrine Peptide™ (PEP™) platform, including clinical data, trial milestones, and financing activities.
News for MBX often centers on its lead candidates canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291. Coverage includes topline and follow-up results from the Phase 2 Avail™ trial of once-weekly canvuparatide in chronic hypoparathyroidism, initiation and progress of the Phase 2a STEADI™ trial of imapextide for post-bariatric hypoglycemia, and design and enrollment updates for the Phase 1 trial of MBX 4291 as a GLP-1/GIP co-agonist prodrug for obesity. MBX also issues releases on expected data readouts, planned regulatory interactions, and preparation for Phase 3 development.
Investors following MBX news will also see announcements related to public equity offerings, cash runway disclosures, and participation in major healthcare and investor conferences such as the J.P. Morgan Healthcare Conference and various cardiometabolic and obesity-focused forums. These items provide context on how the company funds its pipeline and communicates its strategy to the market.
This news page aggregates such updates so readers can track MBX’s clinical milestones, pipeline expansion in obesity, and key regulatory and financing events in one place. For those monitoring MBX stock or the broader endocrine and metabolic drug development space, the feed offers an organized view of how the company reports its progress over time.
MBX Biosciences (Nasdaq: MBX) announced that CEO Kent Hawryluk and CMO Sam Azoulay, M.D., will present at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025.
Presentation format: fireside chat and 1x1 meetings; time: 4:00 p.m.–4:25 p.m. ET; location: New York, NY. The presentation will be webcast live and a replay will be posted approximately two hours after the event and archived on the company website for about 90 days.
Investors can access the live webcast and replay via the events section of the MBX Biosciences investor website.
MBX Biosciences (Nasdaq: MBX) reported positive Phase 2 topline results for once-weekly canvuparatide in hypoparathyroidism, with 63% responder rate at 12 weeks and 79% at six months in the open-label extension.
The company completed an upsized public offering raising approximately $200 million and reported $391.7 million in cash, cash equivalents and marketable securities as of September 30, 2025, which management expects will fund operations into 2029. MBX highlighted planned regulatory interactions in Q1 2026 and a Phase 3 start in Q3 2026, plus ongoing MBX 4291 and imapextide trials with key readouts in 2026.
MBX Biosciences (Nasdaq: MBX) announced that CEO Kent Hawryluk and CMO Sam Azoulay, M.D., will present at four investor conferences in November 2025: Guggenheim (Nov 10, Boston), Stifel (Nov 12, New York), Jefferies (Nov 19, London) and TD Cowen virtual summit (Nov 24).
Formats include fireside chats and 1x1 meetings; listed times are local to each event. Live webcasts and replays will be available in the events section of the company investor website and archived for about 90 days.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, will participate in the Stifel 2025 Virtual Cardiometabolic Forum. The company's leadership, including CEO Kent Hawryluk and CMO Dr. Sam Azoulay, will engage in a fireside chat on September 30, 2025, from 10:00 AM to 10:25 AM ET.
The virtual presentation will be accessible through a live webcast on the company's investor relations website, with a replay available for approximately 90 days following the event.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, has announced the pricing of its upsized public offering. The company is offering 11,108,055 shares of common stock at $18.00 per share, expecting to raise gross proceeds of $199.9 million.
The offering includes a 30-day option for underwriters to purchase up to an additional 1,666,208 shares at the public offering price, less underwriting discounts. The offering is expected to close on September 26, 2025, with J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities serving as joint book-running managers.
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced a proposed public offering of 10 million shares of common stock. The company will also grant underwriters a 30-day option to purchase up to an additional 1.5 million shares.
The offering will be managed by J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities as joint book-running managers, with Citizens Capital Markets and Oppenheimer & Co. serving as co-lead managers. The public offering price has not yet been determined, and the offering is subject to market conditions and SEC registration effectiveness.
MBX Biosciences (Nasdaq: MBX) announced significant positive results from its Phase 2 Avail™ trial of once-weekly canvuparatide for chronic hypoparathyroidism (HP). The trial achieved its primary endpoint with a 63% responder rate at 12 weeks compared to 31% for placebo (p=0.042), and demonstrated a 79% responder rate at 6 months in the open-label extension (OLE).
Key highlights include 100% patient retention through the 12-week study, with 94% entering the OLE. The drug showed positive effects on bone and kidney biomarkers, with a 48% reduction in urine calcium in treated patients. The treatment was well-tolerated with no serious adverse events or discontinuations. Based on these results, MBX plans to initiate a Phase 3 trial in 2026.
MBX Biosciences (Nasdaq: MBX) has announced it will release topline results from its Phase 2 clinical trial of canvuparatide, a potential once-weekly treatment for chronic hypoparathyroidism (HP). The company will host an investor webcast and conference call on Monday, September 22 at 8 AM ET to discuss the Avail™ Phase 2 trial results.
Investors can access the presentation through a live webcast or by dialing 1-877-407-0779 (US) or 1-201-389-0914 (international). The webcast and slide presentation will be available on the company's investor relations website.
MBX Biosciences (Nasdaq: MBX) has initiated its Phase 1 clinical trial of MBX 4291, a novel Precision Endocrine Peptide™ (PEP™) designed for obesity treatment. The drug candidate is a GLP-1/GIP co-agonist prodrug aiming to provide once-monthly dosing with improved weight loss efficacy and better gastrointestinal tolerability.
The trial consists of three parts: a Single Ascending Dose (SAD) study with 5 cohorts, a 4-week Multiple Ascending Dose (MAD) study with 3 cohorts, and a planned 12-week dosing evaluation with up to two larger cohorts. The company expects to report topline results in 2027.
MBX Biosciences (Nasdaq: MBX) has reported its Q2 2025 financial results and pipeline updates. The company maintains a strong financial position with $224.9 million in cash and equivalents, expected to fund operations into mid-2027. Key clinical developments include anticipated Phase 2 Avail™ trial topline results for canvuparatide in hypoparathyroidism in Q3 2025.
The company is advancing multiple clinical programs, including imapextide's Phase 2a trial for post-bariatric hypoglycemia and MBX 4291's Phase 1 trial for obesity, both set to begin in Q3 2025. Q2 financial results showed R&D expenses of $17.7 million (up from $14.4M in Q2 2024) and a net loss of $19.4 million (compared to $15.9M in Q2 2024).